Who is sponsoring RABIT1D?

RABIT1D is sponsored by University of Colorado, Denver.

What condition does RABIT1D study?

RABIT1D studies Coronary Artery Disease, Type 1 Diabetes Mellitus.

What drugs are being tested in RABIT1D?

Interventions: Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow.

What is the status of RABIT1D?

RABIT1D is currently COMPLETED.

Last reviewed 2015-11-09 · How we verify

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486 Phase 4 COMPLETED Results posted

Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type 1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors have had a limited impact. This project called Regadenoson Blood flow in Type 1 Diabetes (RABIT1D) and is proposed as a sub-study of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study, which has established a unique cohort of 656 T1D patients (age 20-55, minimal diabetes duration of 10 yrs) and 764 non-diabetic controls. This cohort is being followed for progression of coronary artery calcification (CAC) measured using the electron beam tomography (EBT) for development of clinical CVD. Participants have been well characterized during the baseline examination (4/00-3/02) and two follow-up re-examinations 3 and 6 years later. The study has provided important insights into the risk factors and possible prevention of premature CVD in T1D. We are proposing assess a subset of this population to determine vasodilatory reserve as it relates to early coronary atherosclerosis in T1D. Hypothesis: that myocardial blood imaging (MBF) reserve can be measured in Type 1 diabetes mellitus (DM) using regadenoson stress cardiac magnetic resonance and that significantly reduced MBF is a marker of extensive atherosclerotic disease correlated to coronary arterial calcification, plaque formation and impaired vasodilatory reserve.

Details

Lead sponsor	University of Colorado, Denver
Phase	Phase 4
Status	COMPLETED
Enrolment	26
Start date	2009-11
Completion	2011-12

Conditions

Coronary Artery Disease
Type 1 Diabetes Mellitus

Interventions

Regadenoson myocardial perfusion imaging
Regadenoson MRI myocardial blood flow

Primary outcomes

Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects. — 1 month
Measurement of Myocardial blood flow measurements (MBF) and myocardial perfusion index obtained from 6 regions within the mid ventricular LV short axis slice.

Countries

United States